Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2022

Cancer immunotherapy in 2022

Checkpoint inhibition beyond anti-PD(L)1 and anti-CTLA4: What progress?

Date

03 Dec 2022

Session

Cancer immunotherapy in 2022

Topics

Tumour Immunology

Tumour Site

Presenters

Han Chong Toh

Authors

H.C. Toh

Author affiliations

  • Medical Oncology Department, NCCS - National Cancer Centre Singapore, 169610 - Singapore/SG

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.